ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 163 filers reported holding ALLOGENE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $426,653 | -22.8% | 134,591 | +21.1% | 0.00% | – |
| Q2 2023 | $552,545 | -86.2% | 111,176 | -86.2% | 0.00% | -100.0% |
| Q1 2023 | $3,997,567 | -0.9% | 808,224 | +26.1% | 0.00% | 0.0% |
| Q4 2022 | $4,034,000 | -51.4% | 641,188 | -16.8% | 0.00% | -66.7% |
| Q3 2022 | $8,306,000 | -30.4% | 770,883 | -26.4% | 0.00% | -25.0% |
| Q2 2022 | $11,942,000 | +30.0% | 1,047,565 | +3.9% | 0.00% | +33.3% |
| Q1 2022 | $9,188,000 | -13.8% | 1,008,536 | +41.1% | 0.00% | 0.0% |
| Q4 2021 | $10,664,000 | +8.7% | 714,662 | +87.2% | 0.00% | 0.0% |
| Q3 2021 | $9,813,000 | +1217.2% | 381,830 | +1236.0% | 0.00% | – |
| Q2 2021 | $745,000 | -13.3% | 28,581 | +17.4% | 0.00% | – |
| Q1 2021 | $859,000 | +16.2% | 24,347 | -16.8% | 0.00% | – |
| Q4 2020 | $739,000 | -36.2% | 29,274 | -4.8% | 0.00% | – |
| Q3 2020 | $1,159,000 | -21.5% | 30,743 | -10.9% | 0.00% | -100.0% |
| Q2 2020 | $1,477,000 | – | 34,496 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 1,798,163 | $5,700,177 | 8.82% |
| Wildcat Capital Management, LLC | 1,920,787 | $6,088,895 | 2.44% |
| TPG GP A, LLC | 18,716,306 | $59,330,690 | 1.02% |
| EcoR1 Capital, LLC | 4,488,200 | $14,227,594 | 0.48% |
| CROSSPOINT FINANCIAL, LLC | 12,000 | $38,040 | 0.40% |
| Coastal Bridge Advisors, LLC | 406,847 | $1,289,705 | 0.35% |
| CAXTON ASSOCIATES LP | 480,104 | $1,521,930 | 0.21% |
| Woodline Partners LP | 5,313,915 | $16,845,111 | 0.20% |
| Rhenman & Partners Asset Management AB | 300,000 | $951,000 | 0.10% |
| Navalign, LLC | 75,365 | $238,907 | 0.09% |